Product
Eureka
For R&D, Eureka makes reading and utilizing patents & technical documents easy.
Eureka AIR
Designed for self-driven R&D workflows. Generate viable solutions, solve complex R&D challenges, empower your innovation with AI.
Eureka Materials
Designed for material experts only. Revolutionize your material R&D, from search, analyze, to developing new materials.
Feature
TechResearch
Generate reliable direction feasibility study reports for your R&D in just a few steps.
TechSeek
Discover and master advanced knowledge NOW. Basics, ideas, possibilities, all at once.
TechMind
As an expert in R&D Theories, TechMind can generates customized viable solutions instantly.
TechRisk
Analyze your overall solution with one click, know your potential R&D risks in advance.
TechMonitor
Get weekly tech updates, stay abreast of the latest tech innovations and key insights.
Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
218 results about "Ischaemia reperfusion" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
Ischemic reperfusion. ischemic reperfusion, n the restoration of blood flow to an area that had previously experienced deficient blood flow. Oxidative stresses associated with this situation may cause damage to the affected tissues or organs.
Methods and apparatus for optimal remote ischemic preconditioning (ORIP) for preventing ischemia-reperfusion injuries to organs
ActiveUS20110238107A1Preventing ischemia-reperfusion injuryMinimize consequencesEvaluation of blood vesselsSensorsReperfusion injuryPercutaneous angioplasty
Ischemia-reperfusion injury commonly results from any surgical procedure requiring stopping of blood supply to an organ followed by reperfusion such as in heart bypass, angioplasty or organ transplant. The invention discloses a method to harness the innate power of repetitive transient ischemia in protecting organs against imminent ischemia-reperfusion, or any patho-physiological insults. This method of optimal remote ischemic preconditioning (ORIP) comprises of utilizing a pair of programmable pneumatic cuffs that inflate / deflate alternately occluding blood circulation to each of the limbs for pre-defined time intervals. The apparatus delivers maximal ORIP dose in shortest possible time either as an EMS procedure during patient transportation to hospital, as elective pre-surgery treatment, or in critical care for preventing multiple-organ-dysfunction-syndrome. ORIP can be self-administered and remotely monitored by clinician especially in chronic patients for homeostasis of malfunctioning target organs. ORIP may also be deployed as adjunct in angioplasty, gene / stem cell heart repair therapies.
Owner:NEOCARDIUM
Targeting complement factor H for treatment of diseases
ActiveUS20080221011A1Improve survivalSenses disorderPeptide/protein ingredientsFactor iiComplement factor I
The invention provides a CR2-FH molecule comprising a CR2 portion comprising CR2 protein or a fragment thereof and a FH portion comprising a factor H protein or a fragment thereof, and pharmaceutical compositions comprising a CR2-FH molecule. Also provided are methods of using the compositions for treatment diseases in which the alternative complement pathway is implicated, such as age-related macular degeneration, rheumatoid arthritis, and ischemia reperfusion.
Owner:MUSC FOUND FOR RES DEV +1
N-hydroxylsulfonamide derivatives as new physiologically useful nitroxyl donors
ActiveUS20070299107A1Increase ischemia/reperfusion injuryIncreased myocardial ischemia/reperfusion injuryBiocideOrganic chemistryDiseaseReperfusion injury
The invention relates to N-hydroxysulfonamide derivatives that donate nitroxyl (HNO) under physiological conditions and are useful in treating and / or preventing the onset and / or development of diseases or conditions that are responsive to nitroxyl therapy, including heart failure and ischemia / reperfusion injury. Novel N-hydroxysulfonamide derivatives release NHO at a controlled rate under physiological conditions, and the rate of HNO release is modulated by varying the nature and location of functional groups on the N-hydroxysulfonamide derivatives.
Owner:THE JOHN HOPKINS UNIV SCHOOL OF MEDICINE +1
N-hydroxylsulfonamide derivatives as new physiologically useful nitroxyl donors
ActiveUS20090163487A1Increase ischemia/reperfusion injuryIncreased myocardial ischemia/reperfusion injuryBiocideOrganic chemistryDiseaseReperfusion injury
The invention relates to N-hydroxylsulfonamide derivatives that donate nitroxyl (HNO) under physiological conditions and are useful in treating and / or preventing the onset and / or development of diseases or conditions that are responsive to nitroxyl therapy, including heart failure and ischemia / reperfusion injury. Novel N-hydroxylsulfonamide derivatives release NHO at a controlled rate under physiological conditions, and the rate of HNO release is modulated by varying the nature and location of functional groups on the N-hydroxylsulfonamide derivatives.
Owner:THE JOHN HOPKINS UNIV SCHOOL OF MEDICINE
Compositions and methods for use of a protease inhibitor and adenosine for preventing organ ischemia and reperfusion injury
InactiveUS20060205671A1Preventing organ ischemia-reperfusionAvoid tissue damageBiocideDipeptide ingredientsReperfusion injuryAdenosine
Methods and compositions including combined use of a serine protease inhibitor and adenosine when administered as a single pharmaceutical composition, concomitantly or sequentially in any order to a living subject for preventing organ ischemia or reperfusion injury. The methods and compositions disclosed herein can be used in such procedures as cardiac surgery, non-surgical cardiac revascularization, organ transplantation, perfusion, ischemia, reperfusion, ischemia-reperfusion injury, oxidant injury, cytokine induced injury, shock induced injury, resuscitations injury or apoptosis.
Owner:EMORY UNIVERSITY
N-Hydroxylsulfonamide Derivatives as New Physiologically Useful Nitroxyl Donors
InactiveUS20110306614A1Quality improvementProlong survival timeBiocideOrganic chemistryDiseaseReperfusion injury
Owner:THE JOHN HOPKINS UNIV SCHOOL OF MEDICINE
Targeting complement factor H for treatment of diseases
ActiveUS7759304B2Improve survivalSenses disorderAntibody mimetics/scaffoldsComplement factor IDisease cause
Owner:MUSC FOUND FOR RES DEV +1
MicroRNA-328 and application of antisense nucleotide thereof for diagnosing, preventing and curing heart diseases
The invention discloses a microRNA-328 and the application of antisense nucleotide thereof for diagnosing and controlling heart diseases; in the invention, a plurality of experiments prove that the microRNA-328 is changed and has pathopoiesia function in heavy heart diseases (atrial fibrillation, ischemia-reperfusion or myocardial fibrosis), and the antisense nucleotide AMO-328 of the microRNA-328has prevention and cure functions to the heart diseases, the microRNA-328 is used as a novel drug effect target spot, so as to finally determine and detect that the peripheral blood microRNA-328 canbe used as a novel biological marker which is used for diagnosing and preventing the heart diseases; in addition, the peripheral blood microRNA-328 expression level of a patient can be detected through fluorescent quantitative PCR and the nanometer microballoon technology enhanced by silver staining, so as to be used for diagnosing and preventing the heart diseases such as atrial fibrillation, long QT syndrome, ischemia-reperfusion or myocardial fibrosis and the like.
Owner:HARBIN MEDICAL UNIVERSITY
Use of HMGB1 for protection against ischemia reperfusion injury
ActiveUS20080004207A1Effective amountPeptide/protein ingredientsAntinoxious agentsReperfusion injuryOrgan damage
Methods and compositions are disclosed for protecting an organ or tissue from inflammation and organ injury following ischemia, reperfusion, and trauma through the administration of an HMGB1 protein within a time period sufficient to protect the organ or tissue from injury.
Owner:UNIVERSITY OF PITTSBURGH +1
Compositions, solutions, and methods used for transplantation
InactiveUS20060166360A1Improve abilitiesIncreases pool sizeVertebrate cellsDead animal preservationLipid formationLipid storage
This invention discloses a method for reducing the intracellular lipid storage material of a cell, tissue, or organ for transplantation and features solutions, methods and kits that induce the metabolic elimination of lipid storage in a cell, tissue, or organ. In one exemplary approach, the process involves contacting a cell, tissue, or organ with a perfusate solution that include catabolic hormones and amino acids, at physiological conditions, to increase lipid export and lipid oxidation. If desired, the cell, tissue, or organ of the invention may also be heat shock preconditioned. The invention can be used to prepare, recondition, or store a cell, tissue, or organ for transplantation by increasing tolerance to ischemia-reperfusion and cold-preservation related injury.
Owner:THE GENERAL HOSPITAL CORP
Compounds for treatment of ischemic injury
The present invention relates to microRNA (miRNA) compounds for use in the treatment of consequences of acute ischemia / reperfusion, a method for preparing miRNA compounds by using test ischemia-reperfusion, test preconditioning and test postconditioning of biological samples, use of the miRNA compounds in the preparation of pharmaceutical compositions having cytoprotective and / or anti-ischemic effect in ischemic cardiac diseases.
Owner:PHARMAHUNGARY 2000
Methods and apparatus for optimal remote ischemic preconditioning (ORIP) for preventing ischemia-reperfusion injuries to organs
ActiveUS8911469B2Strong responsePreventing ischemia-reperfusionEvaluation of blood vesselsCatheterSurgical departmentHeart bypass
Owner:NEOCARDIUM
Inhibitor Of Ischemic Disorders
ActiveUS20100217006A1Effective preventionEffective treatmentGroup 5/15 element organic compoundsBlood disorderBrain edemaBULK ACTIVE INGREDIENT
It is intended to provide a drug which is efficacious in treating and preventing diseases wherein ischemia or an inflammatory substance associated with ischemia participates in the onset or worsening thereof. Because of containing as the active ingredient a substance selected from among farnesol, a farnesol derivative, a tocopherol derivative, a tocotrienol derivative, pharmacologically acceptable salts thereof and solvates thereof, the above-described inhibitor of ischemic disorders can exert therapeutic and preventive effects on diseases wherein ischemia or an inflammatory substance associated with ischemia participates in the onset or worsening thereof (for example, brain infarction, brain edema, cardiac infarction, etc.) not only by the administration in the acute ischemic stage but also by the therapeutic administration in subacute and / or chronic stages after ischemia-reperfusion. It is also intended to provide a farnesol carboxylic acid ester derivative and a method of producing the same.
Owner:FUKUOKA UNIV
Curcumin lipid carrier and preparation method thereof
InactiveCN101396334AGood treatment effectImprove oral bioavailabilityNervous disorderKetone active ingredientsLipid formationSurface-active agents
The invention provides a curcumin lipid carrier and a preparation method thereof for industrialized production. The curcumin lipid carrier comprises the effective remedy dosage of curcumin, lipid and the proper quantities of surface active agent, cosurfactant and additive. The curcumin lipid carrier prepared by the invention has small particle size and high drug loading efficiency and can improve the stability and bioavailability of the drug. The curcumin lipid carrier has good effects of protecting the nerve cell of experimental animal with cerebral ischemia reperfusion, keeping the integrality of the blood brain barrier and preventing and remedying post-stroke brain edema.
Owner:NANJING MEDICAL UNIV
Use of stilbene glycoside in treating dementia
The present invention relates to stilbene glycosie compound and the use of its derivative and medicinal salt in preparing medicine for dementia, especially for Alzheimer disease and vascular dementia. Animal experiment proves that stilbene glycoside compound can resist brain cell damage caused by beta-amyloid protein and hydrogen peroxide, raise the memory capacity of mouse model with scopolaminedementia and A beta dementia and gerbille model with double-sided common carotid artery obstruction caused brain ischemia, inhibit the lipide peroxidation of brain tissue of mouse model with brain ischemia, strengthen the activity of its brain tissue SOD, and reduce the calcium ion density in its brain cells.
Owner:XUANWU HOSPITAL OF CAPITAL UNIV OF MEDICAL SCI
Two bromophenol compounds and application of pharmaceutically-acceptable salts of two bromophenol compounds in preparation of protection drug
ActiveCN102423308AImprove antioxidant capacity (SOD)Improve complianceKetone active ingredientsCardiovascular disorderVeinMedicine
The invention discloses two bromophenol compounds and a pharmaceutical application of their pharmaceutically-acceptable salts, specifically an application in the preparation of a myocardial ischemia-reperfusion injury protection drug. The two compounds and their pharmaceutically-acceptable salts can protect cardiomyocytes during rat heart acute ischemia so as to make rat heart functions complete.After routine intravenous administration, SOD activity after myocardial ischemia-reperfusion is raised, myocardial compliance is improved, serum LDH, serum CK, serum cTnT and MDA level after myocardial ischemia-reperfusion is remarkably reduced, myocardial injury is minimized, and FasmRNA after myocardial ischemia-reperfusion can be remarkably inhibited and reduced so as to inhibit cardiomyocyte apoptosis after myocardial ischemia-reperfusion. Therefore, the two bromophenol compounds and their pharmaceutically-acceptable salts have a clear myocardial ischemia-reperfusion injury protection function, thus providing a new method and means for the clinical treatment of myocardial ischemia-reperfusion injury and opening up a new direction for clinical medication.
Owner:SHANXI MEDICAL UNIV
Application of 5,7-dihydroxy-4'-methoxy flavone preparation extracted from snow lotus in preparation of medicament for treating ischemic stroke
InactiveCN103058975AObvious effectOrganic active ingredientsOrganic chemistryReperfusion injuryMedicine
The invention discloses an application of 5,7-dihydroxy-4'-methoxy flavone preparation extracted from snow lotus in preparation of a medicament for treating ischemic stroke. By effectively extracting the 5,7-dihydroxy-4'-methoxy flavone preparation from the snow lotus and establishing an ischemia reperfusion model of a mouse, the influence of acacetin on the infarct volume and the neurologic impairment caused by ischemia reperfusion injury of the mouse is observed. The study carried out by establishing an SH-SY5Y cell OGD model, testing the cell viability and the cell apoptosis, and demonstrating the integral level of the acacetin shows that the acacetin has the effect of significantly reducing the infarct volume, improving the neurologic function score, promoting the cell survival and reducing the cell apoptosis, clarifies that the acacetin has a neurologic protection effect on the cerebral ischemia reperfusion injury and proves that the 5,7-dihydroxy-4'-methoxy flavone preparation can be well applied to preparing the medicament for treating ischemic stroke and has wide application value.
Owner:朱沂
Function of Dangshen-Huangqi composition in treating the ischemic heart disease
InactiveCN1546065AIncrease coronary blood flowHigh activityUnknown materialsCardiovascular disorderCodonopsis pilosulaThrombus
The invention relates the use of codonopsis pilosula and astragalus root composition in treating ischemic heart diseases, wherein the composition has functions for treating myocardial ischemia, myocardiac infarction, myocardiopathy, and for treating thrombogenesis, lowering blood viscosity, and reducing platelet aggregation.
Owner:LI MIN PHARM FAB OF LIVZON PHARM GRP
Methods of preventing ischemic injury using peripheral nociceptive stimulation
ActiveUS20100292755A1Prevent and reduce ischemia and reperfusion related damageReduce tissue damageInternal electrodesPharmaceutical delivery mechanismIschemic injuryNociceptive Stimulus
Methods of inhibiting ischemia-related and ischemia-reperfusion-related injury are provided. Remote administration of a C-fiber activator or TRPV1 agonist or remote electrical stimulation and activation of TRPV1 reduces ischemia-related tissue damage in subjects at risk for ischemia-related tissue damage. In aspects of the invention, remote application of a TRPV1 agonist inhibits ischemia-related cardiac tissue damage. Methods of inhibiting cardiac tissue damage by topically administering the TRPV1 agonist, capsaicin are provided.
Owner:UNIVERSITY OF CINCINNATI
Medicine for treating angiocardiopathy and cerebrovascular disease and its preparing method
InactiveCN1557403AReduce manufacturing costActive ingredients are clearPowder deliveryUnknown materialsDiseaseSide effect
The medicine for treating cardiac and cerebral vascular diseases is prepared with astragalus root and notoginseng as material, and is Chinese medicine injection, including injection liquid, transfusion liquid and freeze dried powder for injection, prepared through extraction, purification and addition of proper amount of medicinal supplementary material. The medicine has high stability and long effective period, and may be used in intramuscular injection, intravenous injection and intravenous instillation. Pharmacodynamic test shows that the medicine can protect brain against oxygen lack and cardiac muscle damage, raise anaerobic resistance, lower serum LDH and CK activity and reduce myocardial infarction range. The medicine is used in treating cardiac and cerebral vascular diseases and has fast acting, determined curative effect and no toxic side effect.
Owner:陈玲玲
A pharmaceutical composition for treating cardiovascular diseases
ActiveCN104586865AEffectivenessClearly targetedOrganic active ingredientsCardiovascular disorderVascular diseaseCardiac muscle
The invention relates to the field of medicines and discloses a pharmaceutical composition for treating cardiovascular diseases. The composition comprises piceatannol 3'-O-glucoside, polydatin and a piceatannol 3'-O-glucoside derivative. Research found that the composition significantly improves the area of cerebral infarction and the area of myocardial ischemia after ischemia-reperfusion, fundamentally improves various damages caused by ischemia for patients with ischemic cardiovascular diseases, and has a good clinical application prospect.
Owner:KPC PHARM INC
Preparation and detection methods of an animal heart single-cell suspension
InactiveCN107748130ASolve complex operationsAvoid damagePreparing sample for investigationIndividual particle analysisRemove bloodMedicine
Preparation and detection methods of an animal heart single-cell suspension are disclosed. The preparation method includes 1) preparing an animal heart ischemia reperfusion model; 2) preparing an animal isolated hear tissue, flushing the tissue to remove blood, adding heart digestive juice, cutting the tissue into pieces, fully mixing the tissue pieces with the digestive juice and performing digestion; and 3) filtering a mixture solution obtained in the step 2), performing centrifugation, removing a supernatant liquid, terminating digestion, adding a phosphate buffer liquid for suspension, adding an erythrocyte lysis solution, performing centrifugation, removing a supernatant liquid, and adding a phosphate buffer liquid for suspension to obtain the animal heart single-cell suspension. Thepreparation method can reduce destroy to cells, and the single-cell suspension preparation method which is reliable and stable is provided. The number of cells in the prepared suspension is high. Thedetection method is simple to operate and comprehensive in data.
Owner:SHANGHAI PUTUO DISTRICT CENT HOSPITAL
Nitrogenatd trans-stilbene analogs, method for the obtention and medical applications thereof
This invention is related to new nitrogenated trans-stilbene analog compounds, more specifically, imine, pyrrol and Indole derivatives, with procedures for the preparation and use thereof as pharmaceutical compositions for the treatment and / or chemoprevention of those mammalian diseases such as cancer, fibrosclerosis and acute / chronic inflammation, graft-versus-host reaction, ischemic-reperfusion tissue injury in stroke and heart attack, neurodegeneration, and during organ transplantation, whose pathogenic and pathophysiological mechanisms depend on or are significantly contributed by undesirable oxidative stress, angiogenic and proliferative responses.
Owner:DOMINION PHARMAKINE +1
Rationale for IL-1 Beta targeted therapy in sickle cell disease for ischemia-reperfusion induced complications
InactiveUS20100233168A1Block pathological effectExaggerated inflammatoryAntibody ingredientsImmunoglobulinsInflammasomeTarget therapy
Sickle cell patients atypically experience exaggerated inflammatory responses to pathogens that normally cause mild respiratory infections in non-sickle cell humans. There appears to be heightened inflammatory responses to pathogens in combination with hypoxia in sickle cell disease. The novelty of this invention provides a new paradigm to explain the exaggerated inflammatory response of sickle cell disease to pathogens especially when accompanied by hypoxic stress. In particular, sickle cell chest injury and other complications associated with ischemia-reperfusion injury caused by vaso-occlusion can involve co-stimulation of the NALP-3 inflammasome by pathogen associated molecular patterns (PAMPs) and hypoxic-induced danger associated molecular patterns (DAMPs), leading to exaggerated pro-inflammatory responses marked by increased IL-1β secretion and subsequent induction of neutrophilic inflammation. This invention thereby provides the immunologic, biologic and biochemical rationale for IL-1β targeted therapies in sickle cell disease to block the pathological effects of IL-1β that leads to exaggerated inflammatory expressions, including neutrophilic inflammation.
Owner:WANDERER ALAN
New uses of 20(S)-protopanaxadiol
ActiveCN103505462AProne to rashesProne to bleedingOrganic active ingredientsCardiovascular disorderProtopanaxadiolPharmacodynamic Study
The present invention relates to a new use of 20(S)-protopanoxadiol, and in particular, to an application of 20(S)-protopanoxadiol in preparing the medicines for preventing and treating ischemic heart diseases. Pharmacodynamics studies have found that 20(S)-protopanoxadiol can reduce myocardial histological damages caused by ischemia and ischemia reperfusion, reduce enzyme indicators related to infarct size and myocardial necrosis, and reduce the drift of J-spot on an electrocardiogram.
Owner:SHANGHAI INNOVATIVE RESEARCH CENTER OF TRADITIONAL CHINESE MEDICINE
Remedy for disease associated with apoptotic degeneration in ocular cell tissue with the use of SIV-PEDF vector
ActiveCN101180082ALow costEffective neuroprotective therapySenses disorderVectorsPIGMENT EPITHELIUM-DERIVED FACTOREpithelium
Owner:DNAVEC CORP +1
Stephanine and its pharmaceutically acceptable salt and application of solvate for preparing antiarrhythmic medicine
InactiveCN106466317AHas antiarrhythmic effectNo adverse reactionOrganic active ingredientsDispersion deliveryAntiarrhythmic effectStructural formula
The invention relates to stephanine and its pharmaceutically acceptable salt and an application of a solvate for preparing an antiarrhythmic medicine, which belongs to the technical field of medicine. A structural formula of stephanine is shown as a formula (I); the researches on chloroform-induced mice arrhythmia show that stephanine can resist chloroform-induced ventricular fibrillation, preliminary determination is confirmed that the stephanine has antiarrhythmic effect; then barium chloride-induced rat ventricular rhythm test, aconitine intravenous injection-induced rat cardiac rhythm test and rat myocardial ischemia and ischemia reperfusion arrhythmia test are carried out, so that stephanine has good antiarrhythmic effect, and provides a good base for preparing various antiarrhythmic medicines next time.
Owner:YUNNAN UNIV OF TRADITIONAL CHINESE MEDICINE
Application of epicatechin gallate and derivatives thereof for treating or preventing myocardial infarction and other ischemic heart diseases
InactiveCN101984965APharmacological pre-adaptation functionPharmacological postconditioningOrganic active ingredientsCardiovascular disorderReperfusion injuryCvd risk
The invention relates to an application of natural compound epicatechin gallate obtained from tea and derivatives thereof for treating or preventing myocardial infarction and other ischemic heart diseases. The compound is used for preventing the myocardial injury of the heart caused by ischemia-reperfusion, and is a medicament for potentially treating or preventing the heart ischemia / reperfusion injury. Particularly, the compound has a novel effect on protecting the heart and has a function that the enhancement of the myocardial contractility does not depend on the increase of the concentration of calcium ions in myocardial cells. In the invention, it is discovered that the epicatechin gallate (ECG) and the derivatives thereof have pharmacological pre-adaptation functions and have pharmacological post-adaptation functions for the first time, thus the ECG and the derivatives thereof are possibly novel medicaments for treating or preventing myocardial infarction and other ischemic heart diseases. The ECG and the derivatives thereof not only can be used for clinically treating congestive heart diseases through pharmacological post-adaptation but also can be used for medically preventing the patient who suffers from myocardial infarction and then is cured from being subjected to myocardial infarction again through pharmacological pre-adaptation.
Owner:ZHEJIANG HISUN PHARMA CO LTD
High-purity polyphyllin VI preparation method and application
The invention relates to a high-purity polyphyllin VI preparation method and an application, and belongs to the field of Chinese herbal medicine extraction and separation. The method includes the specific steps: roughly crushing Chinese paris rhizome or wake robin medicinal materials, performing ethanol extraction; sequentially performing macroporous adsorption resin, silica gel and reverse-phase material column chromatography on extracting solution; taking ethyl acetate, ethanol and water as eluting agents and filtering, washing and drying sedimentation portions after recovering solvents by eluent to obtain high-purity polyphyllin VI. The method has the advantages that the operation steps are easily repeated, conditions are easily controlled and amplified, the solvents are low in toxicity and easy to recover, and the like. The obtained polyphyllin VI is basically free from organic solvent residues, and the purity of the polyphyllin VI reaches 98% or more. After pharmacodynamical research of the influence of mouse normal pressure hypoxia tolerance, mouse brain ischemia caused by common carotid artery ligation, rat myocardium injury caused by ischemia reperfusion, myocardial infarction caused by rat isolated heart myocardial ischemia and the like, the polyphyllin VI serving as a final product is good in effect and can be used for developing products for treating cardiovascular and cerebrovascular diseases.
Owner:YUNNAN INST OF MATERIA MEDICA
Puerarin derivative and synthetic method and application thereof
ActiveCN103382203AIncrease fat solubilityImprove fat solubility andOrganic active ingredientsNervous disorderChemical synthesisSolubility
A puerarin derivative and a synthetic method and an application thereof belong to the field of cerebrovascular diseases. Selectivity of a vascular dementia therapeutic target is improved by decorating puerarin. The puerarin derivative is indicated through a formula (1) which is as follows. By means of a chemical synthetic method, products are applied to treatment of vascular dementia. Fat solubility and water solubility of the puerarin are improved, receptor selectivity of the puerarin is improved, osmotic pressures inside and outside brain cells are balanced, cellular swelling caused by inflammatory injury is improved, a pharmacologic action of the puerarin itself of improving microcirculation and cholinergic nerve system functions is highlighted, and learning and memory disorders caused by damage caused by ischemia reperfusion are avoided.
Owner:HARBIN UNIV OF COMMERCE
Who we serve
- R&D Engineer
- R&D Manager
- IP Professional
Why Eureka
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Social media
Eureka Blog
Learn More Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com